Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether NHS England is currently in negotiation with Servier regarding the price of Vorasidenib.

This topic has not yet been referred to NHS England for a commercial negotiation by the National Institute for Health and Care Excellence (NICE). This is because the NICE appraisal process has not yet concluded and the preferred assumptions of the independent NICE committee on the comparative benefits and health and care related costs of vorasidenib following consultation have not yet been confirmed.

NHS England has signalled a willingness to engage in discussions with Servier pending further information following the second NICE appraisal committee meeting scheduled for 20 November, which will help to determine what, if any, approach to commercial arrangements, or managed access arrangements may be appropriate for this topic.